408 related articles for article (PubMed ID: 32253134)
41. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
42. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
[TBL] [Abstract][Full Text] [Related]
43. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
44. PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
Fitzal F; Filipits M; Fesl C; Rudas M; Greil R; Balic M; Moinfar F; Herz W; Dubsky P; Bartsch R; Ferree S; Schaper C; Gnant M;
Br J Surg; 2021 Apr; 108(3):308-314. PubMed ID: 33608712
[TBL] [Abstract][Full Text] [Related]
45. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
Mohapatra M; Sarma YS
J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
[TBL] [Abstract][Full Text] [Related]
46. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
[TBL] [Abstract][Full Text] [Related]
47. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Filipits M; Nielsen TO; Rudas M; Greil R; Stöger H; Jakesz R; Bago-Horvath Z; Dietze O; Regitnig P; Gruber-Rossipal C; Müller-Holzner E; Singer CF; Mlineritsch B; Dubsky P; Bauernhofer T; Hubalek M; Knauer M; Trapl H; Fesl C; Schaper C; Ferree S; Liu S; Cowens JW; Gnant M;
Clin Cancer Res; 2014 Mar; 20(5):1298-305. PubMed ID: 24520097
[TBL] [Abstract][Full Text] [Related]
48. CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients.
Kimbung S; Inasu M; Stålhammar T; Nodin B; Elebro K; Tryggvadottir H; Ygland Rödström M; Jirström K; Isaksson K; Jernström H; Borgquist S
Breast Cancer Res; 2020 Nov; 22(1):123. PubMed ID: 33176848
[TBL] [Abstract][Full Text] [Related]
49. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Blok EJ; Kroep JR; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Putter H; van den Bosch J; Maartense E; van Leeuwen-Stok AE; Liefers GJ; Nortier JWR; Rutgers EJT; van de Velde CJH;
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922787
[TBL] [Abstract][Full Text] [Related]
50. Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.
Nye L; Rademaker A; Gradishar WJ
Clin Breast Cancer; 2017 Jul; 17(4):e185-e189. PubMed ID: 28185739
[TBL] [Abstract][Full Text] [Related]
51. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR
Mollon LE; Anderson EJ; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
Clin Breast Cancer; 2020 Jun; 20(3):e232-e243. PubMed ID: 32234362
[TBL] [Abstract][Full Text] [Related]
52. Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer.
Agostinetto E; Giordano L; Torrisi R; De Sanctis R; Masci G; Losurdo A; Zuradelli M; Tinterri C; Gatzemeier W; Testori A; Alloisio M; De Rose F; Fernandes B; Santoro A
Clin Breast Cancer; 2020 Aug; 20(4):e481-e489. PubMed ID: 32279915
[TBL] [Abstract][Full Text] [Related]
53. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR
Noordhoek I; Treuner K; Putter H; Zhang Y; Wong J; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; van de Velde CJH; Schnabel CA; Liefers GJ
Clin Cancer Res; 2021 Jan; 27(1):311-319. PubMed ID: 33109739
[TBL] [Abstract][Full Text] [Related]
54. Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.
Caparica R; Richard F; Brandão M; Awada A; Sotiriou C; de Azambuja E
Clin Breast Cancer; 2020 Jun; 20(3):262-273.e7. PubMed ID: 32229175
[TBL] [Abstract][Full Text] [Related]
55. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
[TBL] [Abstract][Full Text] [Related]
56. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
[TBL] [Abstract][Full Text] [Related]
57. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
58. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
59. Intrinsic and extrinsic flaws of the nomogram predicting bone-only metastasis in women with early breast cancer: An external validation study.
Ouldamer L; Bendifallah S; Chas M; Boivin L; Bedouet L; Body G; Ballester M; Daraï E
Eur J Cancer; 2016 Dec; 69():102-109. PubMed ID: 27821312
[TBL] [Abstract][Full Text] [Related]
60. Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer.
Truin W; Voogd AC; Vreugdenhil G; van der Heiden-van der Loo M; Siesling S; Roumen RM
Ann Oncol; 2012 Nov; 23(11):2859-2865. PubMed ID: 22745216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
